COVID-19, a disease caused by SARS-CoV-2 infection, has become a global pandemic. Patients with myasthenia gravis (MG), often treated with immunosuppressants, might be at higher risk of developing COVID-19 and of demonstrating a severe disease course. We aimed to study prevalence and describe features of COVID-19 in MG patients.

COVID-19 in patients with Myasthenia Gravis: epidemiology and disease course

Businaro, Pietro;Vaghi, Gloria;Diamanti, Luca;Arceri, Sebastiano;Bini, Paola;Colombo, Elena;Cosentino, Giuseppe;Alfonsi, Enrico;Costa, Alfredo;Ravaglia, Sabrina;Mallucci, Giulia;Ballante, Elena;Franciotta, Diego;Gastaldi, Matteo
2021

Abstract

COVID-19, a disease caused by SARS-CoV-2 infection, has become a global pandemic. Patients with myasthenia gravis (MG), often treated with immunosuppressants, might be at higher risk of developing COVID-19 and of demonstrating a severe disease course. We aimed to study prevalence and describe features of COVID-19 in MG patients.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11571/1436194
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 12
social impact